Cole Pharmaceuticals SRL
Cole Pharmaceuticals reported total assets of €1.51m at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Aug 2026).
The score of Cole Pharmaceuticals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +152 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cole Pharmaceuticals's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Aug 2026
- Year ended 31 Dec 2024filed on 16 Jul 2025
- Year ended 31 Dec 2023filed on 24 Mar 2025
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 26 Aug 2022
Cole Pharmaceuticals's financial analysis
- Solvency31.0%sector median: 44.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cole Pharmaceuticals
Cole Pharmaceuticals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0671.904.152
- VAT number
- BE0671904152
- Peppol
- Registered · 0208:0671904152 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Feb 2017
- Registered office
- 1435 Mont-Saint-Guibert
- Latest accounts
- 2025 · filed on 26 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Cole Pharmaceuticals (SRL) has been based in Mont-Saint-Guibert since 2017, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of 390,094 € and equity of 468,254 €; its revenue is not published. Its solvency stands at 31.0%, below the median of its sector (44.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Cole Pharmaceuticals
Companies in the same business, of comparable size and area, outside its group.
- L.F. Will et Cie Wholesale of pharmaceutical and medical goods Wavre · balance sheet €1.21m
- Pharmentum Manufacture of pharmaceutical preparations Kontich · balance sheet €1.94m
- Moleac Belgium Wholesale of pharmaceutical and medical goods Auderghem · balance sheet €1.79m
- Alexo Wholesale of pharmaceutical and medical goods Ham-sur-Heure-Nalinnes · balance sheet €1.45m
- Ophtalmo Vision Care Wholesale of pharmaceutical and medical goods Oudenaarde · balance sheet €1.41m
- Orthomedics Wholesale of pharmaceutical and medical goods Wetteren · balance sheet €1.43m
- Prochiphar Wholesale of pharmaceutical and medical goods Incourt · balance sheet €1.18m
- Cerelo Wholesale of pharmaceutical and medical goods Amel · balance sheet €1.09m
Frequently asked questions about Cole Pharmaceuticals
What is the revenue of Cole Pharmaceuticals?
Cole Pharmaceuticals files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cole Pharmaceuticals?
In Belgium, the VAT number is the company number prefixed with BE: BE0671904152 for Cole Pharmaceuticals, if the company is VAT-registered. Its company number (CBE) is 0671.904.152.
Where is the registered office of Cole Pharmaceuticals?
According to the CBE register, the registered office of Cole Pharmaceuticals is in 1435 Mont-Saint-Guibert.
What is the equity of Cole Pharmaceuticals?
At the close of the 2025 financial year, the equity of Cole Pharmaceuticals amounts to 468,254 €, a solvency of 31.0% of total assets.
Who manages Cole Pharmaceuticals?
The register lists 3 active mandates at Cole Pharmaceuticals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cole Pharmaceuticals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →